Generics in Singapore

Generics in Singapore industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Singapore generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The Singaporean generics market is expected to generate total revenues of $327m in 2015, representing a compound annual growth rate (CAGR) of 10.7% between 2011 and 2015.

Market consumption volume is forecast to reach a total of 89.2% of total pharma volume in 2015.

Singapore has a well-developed pharmaceutical market. The company’s average purchasing power parity (PPP) per capita of GDP was over $61,000 in 2013, $10,000 more than in the US. The country has also been ranked number six healthcare system worldwide by the World Health Organization.

Scope

Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Singapore

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Singapore

Leading company profiles reveal details of key generics market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Singapore generics market with five year forecasts by both value and volume

Macroeconomic indicators provide insight into general trends within the Singapore economy

Reasons to buy

What was the size of the Singapore generics market by value in 2015?

What will be the size of the Singapore generics market in 2020?

What factors are affecting the strength of competition in the Singapore generics market?

How has the market performed over the last five years?

How large is Singapore’s generics market in relation to its regional counterparts?

Companies mentioned

Mylan Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Limited

Table of Contents

TABLE OF CONTENTS

Executive Summary 2

Market value 2

Market value forecast 2

Market volume 2

Market volume forecast 2

Geography segmentation 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 8

Market value 8

Market volume 9

Market Segmentation 10

Geography segmentation 10

Market Outlook 11

Market value forecast 11

Market volume forecast 12

Five Forces Analysis 13

Summary 13

Buyer power 14

Supplier power 15

New entrants 16

Threat of substitutes 17

Degree of rivalry 18

Leading Companies 19

Mylan Inc. 19

Sandoz International GmbH 22

Teva Pharmaceutical Industries Limited 23

Macroeconomic Indicators 26

Country Data 26

Methodology 28

Industry associations 29

Related MarketLine research 29

Appendix 30

About MarketLine 30

List of Tables

Table 1: Singapore generics market value: $ million, 201115(e)

Table 2: Singapore generics market volume: % of total pharma volume, 201115(e)

Table 3: Singapore generics market geography segmentation: $ billion, 2015(e)

Table 4: Singapore generics market value forecast: $ million, 201520

Table 5: Singapore generics market volume forecast: % of total pharma volume, 201520

Table 6: Mylan Inc.: key facts

Table 7: Mylan Inc.: key financials ($)

Table 8: Mylan Inc.: key financial ratios

Table 9: Sandoz International GmbH: key facts

Table 10: Teva Pharmaceutical Industries Limited: key facts

Table 11: Teva Pharmaceutical Industries Limited: key financials ($)

Table 12: Teva Pharmaceutical Industries Limited: key financial ratios

Table 13: Singapore size of population (million), 201115

Table 14: Singapore gdp (constant 2005 prices, $ billion), 201115

Table 15: Singapore gdp (current prices, $ billion), 201115

Table 16: Singapore inflation, 201115

Table 17: Singapore consumer price index (absolute), 201115

Table 18: Singapore exchange rate, 201115

List of Figures

Figure 1: Singapore generics market value: $ million, 201115(e)

Figure 2: Singapore generics market volume: % of total pharma volume, 201115(e)

Figure 3: Singapore generics market geography segmentation: % share, by value, 2015(e)

Figure 4: Singapore generics market value forecast: $ million, 201520

Figure 5: Singapore generics market volume forecast: % of total pharma volume, 201520

Figure 6: Forces driving competition in the generics market in Singapore, 2015

Figure 7: Drivers of buyer power in the generics market in Singapore, 2015

Figure 8: Drivers of supplier power in the generics market in Singapore, 2015

Figure 9: Factors influencing the likelihood of new entrants in the generics market in Singapore, 2015

Figure 10: Factors influencing the threat of substitutes in the generics market in Singapore, 2015

Figure 11: Drivers of degree of rivalry in the generics market in Singapore, 2015

Figure 12: Mylan Inc.: revenues & profitability

Figure 13: Mylan Inc.: assets & liabilities

Figure 14: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 15: Teva Pharmaceutical Industries Limited: assets & liabilities

List of Tables

NA

List of Figures

NA

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports